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Other names: CD314; D12S2489E; NKG2D; NKG2-
D. 
Location: 12p13.2 
Local order: KLRK1 is flanked by KLRD1 (CD94) on 
the centromeric and KLRC4 (NKG2F) on the telomeric 
side. The 3' end of the KLRC4 transcript includes the
first non-coding exon found at the 5' end of the 
adjacent KLRK1 gene transcript. 
Note: KLRK1 is on chromosome 12p13.2-p12.3 at 
10,416,857-10,454,012. 
KLRK1 is a member of the C-type lectin-like family of 
type II cell surface glycoproteins. It is expressed by NK 
cells, CD8+ T cells, gamma/delta-TcR+ T cells, and  
minor subset of CD4+ T cells. KLRK1 associates with 
the DAP10 transmembrane adapter protein and 
transmits activating signalings into these lymphocytes. 
DNA/RNA 
Note: KLRK1 is present on chromosome 12 within a 
cluster of genes referred to as the 'NK complex' (NKC) 
because several genes that are preferentially expressed 
by NK cells are located in this region, including on the 
centromeric side KLRD1 (CD94) and on the telomeric 
side KLRC4 (NKG2F), KLRC3 (NKG2E), KLRC2 
(NKG2C), and KLRC1 (NKG2A). 
Description 
The KLRK1 gene is 37,793 bases located on the 
negative strand of chromosome 12 spanning 
10,416,219 to 10,454,012 bp. ENTREZ database 
predicts 12 exons. 
Three alleles of KLRK1 differing by substitutions at 
only two nucleotide positions, of which one is 
nonsynonymous and the other synonymous, have been 
reported. 
Transcription 
There is evidence for alternative splicing of KLRK1, 
but only one isoform encoding a functional protein has 
been described in humans. In one of the KLRK1 splice 
variants the fourth exon of KLRC4 is spliced to the5-
prime end of KLRK1. KLRK1 is transcribed by NK 
cells, gamma/delta-TcR+ T cells, CD8+ T cells and 
some CD4+ T cells. 
Transcription of KLRK1 is enhanced by stimulation of 
NK cells with IL-2 or IL-15 and decreased by culture 
with TGF-beta. 
Protein 
Note: KLRK1 is a type II membrane glycoprotein 
expressed as a disulfide-bonded homodimer on the cell 
surface. Expression of KLRK1 on the cell surface 
requires its association with DAP10, which is a type I 
adapter protein expressed as a disulfide-bonded 
homodimer. On the cell surface, the receptor complex 
is a hexamer; two disulfide-bonded KLRK1/NKG2D 
homodimers each paired with two DAP10 disulfide-
bonded homodimers. A charged amino acid residue 
(aspartic acid) centrally located within the 
transmembrane region of DAP10 forms a salt bridge 
with a charged amino acid residue (arginine) in the
transmembrane region of KLRK1/NKG2D to stabilize 
the receptor complex. 
Description 
KLRK1 is a type II membrane protein comprising 216 
amino acids with a predicted molecular weight of 
25143 kD. The protein has an N-terminal intracellular 
region, a transmembrane domain, and a C-terminal 
extracellular region with a single C-type lectin-like 
domain. 
KLRK1 is expressed on the cell surface as a disulfide-
bonded homodimer with a molecular weight of 
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approximately 42 kd when analyzed under reducing 
conditions and approximately 80 kd under non-
reducing conditions. 
A cysteine residue just outside the transmembrane 
region forms the disulfide bond joining the two 
subunits of the homodimer. There are three potential 
sites for N-linked glycosylation in the extracellular 
region of KLRK1. 
Treatment of the KLRK1 glycoprotein with N-
glycanase reduces the molecular weight to 
approximately the size of the core polypeptide. The 
protein has an N-terminal intracellular region, a 
transmembrane domain, a membrane-proximal stalk 
region, and an extracellular region with a single C-type 
lectin-like domain. 
Expression 
KLRK1 is transcribed by NK cells, gamma/delta-TcR+ 
T cells, CD8+ T cells and some CD4+ T cells. 
Localisation 
KLRK1 is expressed as a type II glycoprotein on the 
cell surface of NK cells, gamma/delta-TcR+ T cells, 
CD8+ T cells and some CD4+ T cells. 
Function 
KLRK1 binds to at least seven distinct ligands: MICA, 
MICB, ULBP-1, ULBP-2, ULBP-3, ULBP-4, and 
RAET1G. These ligands are type I glycoproteins with 
homology to MHC class I. 
The KLRK1 ligand are frequently over-expressed on 
tumor cells, virus-infected cells, and 'stressed' clls. 
The crystal structure of KLRK1 bound to MICA has 
been reported. After binding to its ligand, KLRK1 
transmits an activating signal via the DAP10 adapter 
subunit. 
DAP10 has a YxxM motif in its cytoplasmic domain, 
which upon tyrosine phosphorylation binds to Vav and 
the p85 subunit of PI3-kinase, causing a downstream 
cascade of signaling in T cells and NK cells. 
Homology 
NKG2-D type II integral membrane protein [Pan 
troglodytes] NP_001009059; 
NKG2D protein [Macaca mulatta] NP_001028061;  
NKG2D receptor [Macaca fascicularis] CAD19993;  
NKG2D [Callithrix jacchus] ABN45890;  
NKG2D [Papio anubis] ABO09749;  
NKG2-D type II integral membrane protein [Pongo 
pygmaeus] Q8MJH1;  
putative immunoreceptor NKG2D [Bos taurus] 
CAJ27114; 
NKG2-D type II integral membrane protein [Sus 
scrofa] Q9GLF5; 
NKG2-D isoform a [Mus musculus] NP_149069; 
NKG2-D isoform b [Mus musculus] NP_001076791; 
killer cell lectin-like receptor subfamily K, member 1 
[Rattus norvegicus] NP_598196. 
Mutations 
Note: None identified. 
Implicated in 
Cancer 
Note: Many types of cancer (carcinomas, sarcomas, 
lymphomas, leukemias) over-express the ligands for 
KLRK1. In some cases, this renders the tumor cells 
susceptible to killing by activated KLRK1-bearing NK 
cells. Some tumors shed or secrete soluble ligands that 
bind to KLRK1 and down-regulate expression of the 
KLRK1 receptor on NK cells and T cells, potentially to 
evade attack by these immune effector cells. 
Viral infection 
Note: Viral infection of cells can induce transcription 
and cell surface expression of ligands for KLRK1, 
rendering these infected cells susceptible to attack by 
NK cells and T cells. Some viruses, for example 
cytomegalovirus, encodes proteins that intercept the 
ligand proteins intracellularly and prevent their 
expression on the surface of virus-infected cells. 
Rheumatoid arthritis 
Note: An expansion of CD4+, CD28- T cells 
expressing KLRK1 was observed in the joints of 
patients with rheumatoid arthritis and KLRK1 ligands 
were detected on synovial cells in the inflamed tissue. 
Type I diabetes 
Note: Peripheral blood NK cells and T cells in patients 
with type I diabetes demonstrate a slightly decreased 
amount of expression of KLRK1 on the cell surface, 
independent disease duration, similar to prior 
observations in the NOD mouse. 
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